Ruxolitinib for steroid-resistant graft-versus-host disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new pill, ruxolitinib, for people whose acute graft-versus-host disease (a complication after a stem cell transplant) is not improving with steroids. It aims to see if it can better control the disease and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older and able to swallow tablets.
- You have had a stem cell transplant from a donor.
- You have been diagnosed with grade 2 to 4 acute graft-versus-host disease that requires treatment.
- Your current steroid treatment is not working well or you cannot reduce the dose safely.
- You have not received more than one other experimental treatment for this condition.
- You do not have any active infections or other serious medical problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if ruxolitinib can help people with chronic graft-versus-host disease (cGvHD) that hasn't improved with steroids. It's for Chinese patients aged 12 and older who have moderate to severe cGvHD after a stem cell transplant.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests whether adding ruxolitinib to standard steroid treatment works better than steroids alone for people with moderate to severe chronic graft-versus-host disease (cGVHD). cGVHD is a condition where donor immune cells attack the body after a stem cell transplant.
This trial tests whether starting ruxolitinib early, guided by a blood marker, can prevent acute graft-versus-host disease (aGVHD) after a stem cell transplant. It's for people who have already had a transplant and are at risk for this complication.
This trial tests whether adding stem cells (remestemcel-L) to ruxolitinib—a medication that helps control the immune system—can help treat severe graft-versus-host disease (GVHD) that hasn't responded to steroids. GVHD is a complication after bone marrow or stem cell transplant where the new immune cells attack your body.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Hear when a new Steroid-refractory Acute Graft-versus-host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.